WO2005023183A3 - Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use - Google Patents

Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use Download PDF

Info

Publication number
WO2005023183A3
WO2005023183A3 PCT/US2004/026911 US2004026911W WO2005023183A3 WO 2005023183 A3 WO2005023183 A3 WO 2005023183A3 US 2004026911 W US2004026911 W US 2004026911W WO 2005023183 A3 WO2005023183 A3 WO 2005023183A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
nitrosated
nitrosylated
optionally
diseases
Prior art date
Application number
PCT/US2004/026911
Other languages
French (fr)
Other versions
WO2005023183A2 (en
Inventor
David S Garvey
L Gordon Letts
Manuel Worcel
Richard A Earl
Maiko Ezawa
Xinqin Fang
Subhash P Khanapure
Chia-En Lin
Ramani R Ranatunge
Cheri A Stevenson
Original Assignee
Nitromed Inc
David S Garvey
L Gordon Letts
Manuel Worcel
Richard A Earl
Maiko Ezawa
Xinqin Fang
Subhash P Khanapure
Chia-En Lin
Ramani R Ranatunge
Cheri A Stevenson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitromed Inc, David S Garvey, L Gordon Letts, Manuel Worcel, Richard A Earl, Maiko Ezawa, Xinqin Fang, Subhash P Khanapure, Chia-En Lin, Ramani R Ranatunge, Cheri A Stevenson filed Critical Nitromed Inc
Priority to EP04781571A priority Critical patent/EP1668008A4/en
Priority to CA002536975A priority patent/CA2536975A1/en
Priority to AU2004270162A priority patent/AU2004270162B2/en
Priority to JP2006524731A priority patent/JP2007504136A/en
Publication of WO2005023183A2 publication Critical patent/WO2005023183A2/en
Publication of WO2005023183A3 publication Critical patent/WO2005023183A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/39—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups
    • C07C205/40—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups and esterified hydroxy groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

The invention describes novel nitrosated and/or nitrosylated diuretic compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated diuretic compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one diuretic compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; and (1) treating nephropathy.
PCT/US2004/026911 2003-08-28 2004-08-20 Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use WO2005023183A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04781571A EP1668008A4 (en) 2003-08-28 2004-08-20 Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
CA002536975A CA2536975A1 (en) 2003-08-28 2004-08-20 Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
AU2004270162A AU2004270162B2 (en) 2003-08-28 2004-08-20 Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
JP2006524731A JP2007504136A (en) 2003-08-28 2004-08-20 Nitrosated and nitrosylated diuretic compounds, compositions and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49830903P 2003-08-28 2003-08-28
US60/498,309 2003-08-28
US53554204P 2004-01-12 2004-01-12
US60/535,542 2004-01-12

Publications (2)

Publication Number Publication Date
WO2005023183A2 WO2005023183A2 (en) 2005-03-17
WO2005023183A3 true WO2005023183A3 (en) 2005-10-13

Family

ID=34278590

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2004/026911 WO2005023183A2 (en) 2003-08-28 2004-08-20 Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
PCT/US2004/026910 WO2005023182A2 (en) 2003-08-28 2004-08-20 Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2004/026910 WO2005023182A2 (en) 2003-08-28 2004-08-20 Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use

Country Status (6)

Country Link
US (2) US7282519B2 (en)
EP (2) EP1667643A4 (en)
JP (2) JP2007504135A (en)
AU (2) AU2004270161A1 (en)
CA (2) CA2536967A1 (en)
WO (2) WO2005023183A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895556B2 (en) 2007-12-26 2014-11-25 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9284275B2 (en) 2007-01-11 2016-03-15 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
US8008283B2 (en) * 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
JP2007529459A (en) * 2004-03-17 2007-10-25 ノバルティス アクチエンゲゼルシャフト Use of renin inhibitors in therapy
US8053047B2 (en) 2004-04-02 2011-11-08 Curwood, Inc. Packaging method that causes and maintains the preferred red color of fresh meat
US8470417B2 (en) 2004-04-02 2013-06-25 Curwood, Inc. Packaging inserts with myoglobin blooming agents, packages and methods for packaging
US8545950B2 (en) * 2004-04-02 2013-10-01 Curwood, Inc. Method for distributing a myoglobin-containing food product
US8741402B2 (en) * 2004-04-02 2014-06-03 Curwood, Inc. Webs with synergists that promote or preserve the desirable color of meat
US7867531B2 (en) 2005-04-04 2011-01-11 Curwood, Inc. Myoglobin blooming agent containing shrink films, packages and methods for packaging
US8029893B2 (en) 2004-04-02 2011-10-04 Curwood, Inc. Myoglobin blooming agent, films, packages and methods for packaging
US8110259B2 (en) 2004-04-02 2012-02-07 Curwood, Inc. Packaging articles, films and methods that promote or preserve the desirable color of meat
US7618594B2 (en) * 2004-08-18 2009-11-17 Geno Llc Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
JP5421530B2 (en) 2004-08-18 2014-02-19 ゲノ エルエルシー Conversion of nitrogen dioxide (NO2) to nitrogen oxide (NO)
WO2006041855A2 (en) * 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
EP1828155A4 (en) * 2004-11-15 2011-04-20 Nicox Sa Diuretic compounds comprising heterocyclic nitric oxide donor groups,compositions and methods of use
JP2008533031A (en) * 2005-03-09 2008-08-21 ニトロメッド インコーポレーティッド Organic nitric oxide enhancing salts, compositions and methods of use of angiotensin II antagonists
US20090214618A1 (en) 2005-05-27 2009-08-27 Schoenfisch Mark H Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20070149526A1 (en) * 2005-10-17 2007-06-28 Neurotherapeutics Pharma, L.L.C. Diuretic and diuretic-like compound analogs
US20080274171A1 (en) * 2005-10-18 2008-11-06 Nicoletta Almirante Renin Inhibitors Nitroderivatives
US20070185065A1 (en) * 2006-02-03 2007-08-09 Vikramjit Chhokar Combination therapy for coronary artery disease
CN101024643A (en) * 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 Imidazo-5-carboxylic-acid derivatives, its preparing method and use
CA2652636A1 (en) 2006-05-29 2007-12-06 Nicox S.A. Nitrated heterocyclic compounds as endothelin receptor antagonist
TW200831463A (en) * 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
WO2008058402A1 (en) 2006-11-17 2008-05-22 Queen's University At Kingston Compounds and methods for treating protein folding disorders
CA2671816C (en) 2006-12-06 2012-06-05 Shanghai Allist Pharmaceutical., Inc. Salts of imidazole-5-carboxylic acid derivatives, a method for preparing same and pharmaceutical compositions comprising same
AU2007334521B2 (en) * 2006-12-13 2012-03-29 Merck & Co., Inc. Angiotensin II receptor antagonists
TW200831079A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Angiotensin II receptor antagonists
EP2131903B1 (en) 2007-03-23 2018-01-24 Geno LLC Conversion of nitrogen dioxide (no2) to nitric oxide (no)
CN101317842A (en) 2007-06-07 2008-12-10 上海艾力斯医药科技有限公司 Treating uses of imidazole-5-carboxylic acid derivant
US20100316622A1 (en) * 2007-11-02 2010-12-16 University Of Miami Diagnosis and treatment of cardiac disorders
AR069340A1 (en) * 2007-11-26 2010-01-13 Merck & Co Inc ANGIOTENSIN II RECEIVER ANTAGONISTS
CA2713049C (en) 2008-01-28 2017-02-28 Geno Llc Conversion of nitrogen dioxide (no2) to nitric oxide (no)
JP2011513268A (en) * 2008-02-26 2011-04-28 ニコックス エス エイ Angiotensin II receptor antagonist
CA2712695A1 (en) * 2008-02-26 2009-09-03 Nicoletta Almirante New angiotensin ii receptor blocker derivatives
WO2009140111A1 (en) * 2008-05-15 2009-11-19 Merck & Co., Inc. Angiotensin ii receptor antagonists
CN101596189A (en) * 2008-06-05 2009-12-09 上海艾力斯生物医药有限公司 The Pharmaceutical composition that contains imidazole-5-carboxylic acid derivatives
EP2313417A1 (en) * 2008-06-09 2011-04-27 Nicox S.A. Angiotensin ii receptor antagonists
AR073259A1 (en) * 2008-07-29 2010-10-28 Merck & Co Inc USEFUL FUROSEMIDE DERIVATIVES AS DIURETICS
US8607785B2 (en) 2008-08-21 2013-12-17 Geno Llc Systems and devices for generating nitric oxide
JP2012511002A (en) 2008-12-05 2012-05-17 メルク・シャープ・エンド・ドーム・コーポレイション Nitrooxy derivatives as angiotensin II receptor antagonists
US8372862B2 (en) 2009-06-02 2013-02-12 Korea Research Institute Of Chemical Technology Pharmaceutical composition for preventing or treating osteoporosis or obesity comprising phenyltetrazole derivative
CA2763804C (en) 2009-06-22 2018-02-06 Geno Llc Nitric oxide therapies
EP4249001A3 (en) 2009-08-21 2023-11-29 Novan, Inc. Topical gels
WO2011022680A2 (en) 2009-08-21 2011-02-24 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
AU2010321707B2 (en) * 2009-11-20 2016-03-17 VERO Biotech LLC. Nitric oxide delivery system
CN107595828A (en) 2010-01-15 2018-01-19 国立健康与医学研究所 For treating the compound of autism
US20130079348A1 (en) * 2010-03-03 2013-03-28 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
JO3350B1 (en) 2011-03-07 2019-03-13 Merck Sharp & Dohme Heterocyclic derivatives containing primary amino groups and diazeniumdiolates
EP2732815A1 (en) 2012-11-16 2014-05-21 Neurochlore Modulators of intracellular chloride concentration for treating fragile X syndrome
WO2015091857A1 (en) 2013-12-20 2015-06-25 Fondazione Istituto Italiano Di Tecnologia Modulators of intracellular chloride concentration for treating down syndrome
CN104447763B (en) * 2014-12-18 2017-05-17 南京华威医药科技开发有限公司 Biphenyl tetrazole compound
LT6401B (en) 2015-07-28 2017-06-12 Vilniaus Universitetas Selective inhibitors of carbonic anhydrase
EP3348548A4 (en) * 2015-09-07 2019-04-03 Zhejiang Huahai Pharmaceutical Co., Ltd Nitric oxide-releasing prodrug molecule

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992451A (en) * 1985-06-14 1991-02-12 Sankyo Company, Limited 1,4-dihydropyridine derivatives

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3254076A (en) 1966-05-31 Sulfamyl hydro
FR6869E (en) 1907-03-25 Vve Materne Nee Leonie Lagnier Tie button
US38103A (en) * 1863-04-07 Improvement in slate-roofing
US37234A (en) * 1862-12-23 Improvement in harrows
US10715A (en) * 1854-03-28 Improvement in track-clearers for railroads
GB863474A (en) 1958-08-13 1961-03-22 Knud Abildgaard Benzothiadiazine derivatives and their preparation
CH392526A (en) 1959-10-08 1965-05-31 Ciba Geigy Process for the preparation of 3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxydes
US3058882A (en) * 1959-12-28 1962-10-16 Hoechst Ag N'-substituted-3-carboxy-6-halo-sulfanilamide and derivatives thereof
NL283250A (en) 1961-09-15
GB1129360A (en) 1966-09-12 1968-10-02 Merck & Co Inc Sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxides
US4315348A (en) * 1979-05-08 1982-02-16 Hans Oetiker Mechanical lock for clamps
US4559340A (en) 1983-11-25 1985-12-17 Schering Corporation Antihypertensive agents
US4780401A (en) * 1984-04-09 1988-10-25 Ciba-Geigy Corporation Novel monoclonal antibodies to human renin and hybridoma cells, processes for their preparation and their applications
PH21213A (en) 1984-10-26 1987-08-21 Fujisawa Pharmaceutical Co Benzene- and pyrazole- fused heterocyclic compound and pharmaceutical composition comprising the same
US4845079A (en) * 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) * 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) * 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) * 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US4980283A (en) * 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5089471A (en) * 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US5034512A (en) * 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) * 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) * 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5036054A (en) * 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5036053A (en) * 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
US5428061A (en) * 1988-09-15 1995-06-27 Schwarz Pharma Ag Organic nitrates and method for their preparation
DE3841520A1 (en) * 1988-12-09 1990-06-13 Hoechst Ag ENZYME-INFRINGING DERIVATIVES OF DIPEPTIDES, METHOD FOR THE PRODUCTION THEREOF, METHODS CONTAINING THEM AND THEIR USE
US5106835A (en) * 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
JPH02180867A (en) 1988-12-29 1990-07-13 Green Cross Corp:The Dihydropyridine derivative
DE4004820A1 (en) * 1989-08-05 1991-04-25 Bayer Ag RENININHIBITORS, METHOD FOR THE PREPARATION AND THEIR USE IN MEDICINAL PRODUCTS
US5063208A (en) * 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5284872A (en) * 1989-09-12 1994-02-08 Schwarz Pharma Ag Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof
US5098924A (en) * 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5114937A (en) * 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
DE122010000024I1 (en) * 1990-02-19 2010-07-08 Novartis Ag acyl compounds
US5095119A (en) * 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5064965A (en) * 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5075451A (en) * 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
JP2929656B2 (en) * 1990-03-28 1999-08-03 ブラザー工業株式会社 sewing machine
AU8534291A (en) * 1990-08-10 1992-03-02 G.D. Searle & Co. Renal-selective angiotensin ii antagonists for treatment of hypertension
US5250548A (en) * 1990-09-10 1993-10-05 Abbott Laboratories Angiotensin II receptor antagonists
US5252165A (en) * 1990-09-20 1993-10-12 United Technologies Corporation Method of making contoured fiber reinforced body
US5071837A (en) * 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
US5109869A (en) * 1991-01-22 1992-05-05 Baxter International Inc. Disposable uterine sound device
US5380758A (en) * 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
IL101860A0 (en) * 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
US5177097A (en) * 1991-07-24 1993-01-05 E. R. Squibb & Sons, Inc. Acyl amidine and acyl, guanidine substituted biphenyl derivatives
US5256695A (en) * 1991-07-24 1993-10-26 E. R. Squibb & Sons, Inc. Acyl amidine and acyl guanidine substituted biphenyl derivatives
IT1250749B (en) * 1991-08-02 1995-04-21 Luso Farmaco Inst HETEROCYCLIC COMPOUNDS ACTIVATED IN II ANTAGONIST
TW213903B (en) 1991-08-16 1993-10-01 Boehringer Ingelheim Kg
US5234936A (en) * 1991-10-24 1993-08-10 American Home Products Corporation Pyrimidocycloalkanes as a ii antagonists
US5326776A (en) * 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
US6010715A (en) * 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5650447A (en) * 1992-08-24 1997-07-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitric oxide-releasing polymers to treat restenosis and related disorders
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2158737A1 (en) * 1993-04-07 1994-10-13 Keizo Tanikawa Pyrazole derivatives
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5451597A (en) * 1993-05-27 1995-09-19 G.D. Searle & Co. Treatment of circulatory disorders using n-substituted (α-imidazolyl-toluyl) pyrrole angiotensin II antagonists
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
DE4321306A1 (en) * 1993-06-26 1995-01-05 Sanol Arznei Schwarz Gmbh disulfide
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
AU696868B2 (en) * 1994-03-29 1998-09-17 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles
GB9406573D0 (en) * 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
DE19515970A1 (en) * 1995-05-02 1996-11-07 Bayer Ag Acetylsalicylsäurenitrate
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
JP3534775B2 (en) * 1995-06-07 2004-06-07 オーソ―マクニール ファーマシューティカル，インコーポレイテッド Transdermal patches and methods for administering 17-deacetylnorgestimate alone or in combination with estrogens
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US5773434A (en) 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
SK56798A3 (en) * 1995-10-30 1998-12-02 Smithkline Beecham Corp Protease inhibitors, pharmaceutical composition containing them and their use
US6083947A (en) 1996-01-29 2000-07-04 The Regents Of The University Of California Method for treating sexual dysfunctions
NZ331549A (en) 1996-01-29 2000-09-29 Univ California Compounds useful in treating sexual dysfunction
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
TW394917B (en) * 1996-04-05 2000-06-21 Matsushita Electric Ind Co Ltd Driving method of liquid crystal display unit, driving IC and driving circuit
KR100387658B1 (en) * 1996-04-12 2003-08-19 지.디. 썰 엘엘씨 Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
US5807847A (en) * 1996-06-04 1998-09-15 Queen's University At Kingston Nitrate esters
US6242443B1 (en) 1996-06-21 2001-06-05 Novo Nordisk Ais 1,2,4-benzothiadiazine derivatives, their preparation and use
IT1288123B1 (en) 1996-09-04 1998-09-10 Nicox Sa USE OF NITRO-DERIVATIVES FOR URINARY INCONTINENCE
AU4345297A (en) 1996-09-17 1998-04-14 Regents Of The University Of California, The Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US6232336B1 (en) * 1997-07-03 2001-05-15 The United States Of America As Represented By The Department Of Health And Human Services Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same
CA2306817A1 (en) 1997-10-27 1999-05-06 Cortex Pharmaceuticals Inc. Treatment of schizophrenia with ampakines and neuroleptics
US6943159B1 (en) 1998-02-18 2005-09-13 Neurosearch A/S Compounds and their use as positive AMPA receptor modulators
RU2214405C2 (en) 1998-02-18 2003-10-20 НьюроСёрч А/С Novel compounds and their application as positive modulators of ampa-receptors
CA2318778A1 (en) * 1998-02-25 1999-09-02 Merck & Co., Inc. Method for decreasing qt dispersion or inhibiting the progression of qt dispersion with an angiotensin ii receptor antagonist
US20020115687A1 (en) 1998-04-24 2002-08-22 Evan Beckman Method and composition for restoring diuretic and renal function
IT1301759B1 (en) 1998-06-19 2000-07-07 Nicox Sa NITRATED SALTS OF ANTI-HYPERTENSIVE DRUGS
US6122179A (en) * 1998-06-29 2000-09-19 Lucent Technologies Inc. Mounting tree for power transfer devices used in hybrid fiber/coaxial systems
JP2002528495A (en) * 1998-10-30 2002-09-03 ニトロメド インコーポレーテッド Nitrosated and nitrosylated non-steroidal anti-inflammatory compounds, compositions and methods of use
WO2001035961A1 (en) * 1999-10-29 2001-05-25 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US20050038017A1 (en) 1999-12-22 2005-02-17 Wolff Andrew A. Method and composition for restoring diuretic and renal function
EP1132382A1 (en) 2000-03-08 2001-09-12 Farma Invent B.V. 3-Oxy-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadazine-1,1-dioxide derivatives having diuretic and/or natriuretic activity
WO2001065935A1 (en) 2000-03-08 2001-09-13 Yoram Vodovotz Kidney perfusion solution containing nitric oxide donor
HRP20000162B1 (en) 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
EP1270004B1 (en) 2000-03-31 2010-06-09 Eisai R&D Management Co., Ltd. Use of gamma-tocotrienol as diuretic
US6240603B1 (en) * 2000-05-31 2001-06-05 Paul M. Craig, Jr. Hose clamp with stepless internal clamping surface and method of making the same
AU2001270070B2 (en) * 2000-06-22 2006-03-16 Nitromed, Inc. Nitrosated and nitrosylated taxanes, compositions and methods of use
EP1322316B1 (en) 2000-09-21 2009-07-01 Henderson Morley Research and Development Limited Diuretic or sulphonylurea for use in antiviral treatment
CN1265788C (en) 2000-11-21 2006-07-26 三共株式会社 Medicinal compositions
ATE341343T1 (en) 2000-12-26 2006-10-15 Sankyo Co MEDICAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE IMPROVEMENT AGENT
US6974869B2 (en) * 2001-09-18 2005-12-13 Bristol-Myers Squibb Pharma Company Piperizinones as modulators of chemokine receptor activity
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
AU2003214210A1 (en) 2002-03-18 2003-10-08 Scios Inc. Treatment of congestive heart failure with natriuretic peptide and a diuretic
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
PE20040468A1 (en) 2002-05-17 2004-09-14 Novartis Ag ORGANIC COMPOUND COMBINATION
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
JP2006511567A (en) 2002-12-16 2006-04-06 キング・ファーマシューティカルズ・インコーポレーテッド Methods and dosage forms for reducing heart attacks in hypertensive individuals using diuretics or using a combination of diuretics and ACE inhibitors
FI20030015A0 (en) 2003-01-03 2003-01-03 Orion Corp A method of treating renal failure
TW200500070A (en) 2003-04-25 2005-01-01 Novacardia Inc Method of improved diuresis in individuals with impaired renal function
WO2004111014A1 (en) * 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
WO2005014043A1 (en) 2003-07-16 2005-02-17 Boehringer Ingelheim International Gmbh Chlorthalidone combinations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992451A (en) * 1985-06-14 1991-02-12 Sankyo Company, Limited 1,4-dihydropyridine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1668008A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284275B2 (en) 2007-01-11 2016-03-15 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US8895556B2 (en) 2007-12-26 2014-11-25 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9422282B2 (en) 2010-04-01 2016-08-23 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV

Also Published As

Publication number Publication date
JP2007504135A (en) 2007-03-01
EP1667643A4 (en) 2008-03-05
EP1667643A2 (en) 2006-06-14
EP1668008A4 (en) 2009-02-25
CA2536967A1 (en) 2005-03-17
US7282519B2 (en) 2007-10-16
WO2005023183A2 (en) 2005-03-17
AU2004270162A1 (en) 2005-03-17
WO2005023182A2 (en) 2005-03-17
US20050059655A1 (en) 2005-03-17
JP2007504136A (en) 2007-03-01
US20070238740A1 (en) 2007-10-11
WO2005023182A3 (en) 2006-10-19
CA2536975A1 (en) 2005-03-17
AU2004270162B2 (en) 2010-05-13
AU2004270161A1 (en) 2005-03-17
EP1668008A2 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
WO2005023183A3 (en) Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
WO2005018561A3 (en) Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2006055542A3 (en) Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use
WO2006091716A3 (en) Nitric oxide enhancing diuretic compounds, compositions and methods of use
WO2004101562A3 (en) Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
WO2006041855A3 (en) Compositions and methods using apocynin compounds and nitric oxide donors
EP1717238A4 (en) Fungicidal heterocyclic compounds
WO2004043367A3 (en) Fused heterocyclic compounds and use thereof
DE60315323D1 (en) PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF SUFFERING THROUGH CHEMOKINS
DK1658269T3 (en) Condensed compounds which inhibit the vanilloid receptor subtype 1 (VR1) receptor
WO2005030135A3 (en) Nitrosated glutamic acid compounds, compositions and methods of use
WO2003093269A3 (en) Substituted pyrazolo-pyrimidine-4-ones
WO2007019448A3 (en) Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use
WO2004013120A8 (en) Novel benzodioxoles
WO2006113552A8 (en) Cyanoarylamines
WO2006005609A3 (en) Substituted oxindol derivatives and medicaments containing the same
EP1499308A4 (en) Tri-substituted heteroaryls and methods of making and using the same
BRPI0610312B8 (en) walking assistance device
WO2004078757A3 (en) Synthesis of 5-substituted 7-azaindoles and 7-azaidonines
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
WO2006099058A3 (en) Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
MX2007007100A (en) Benzisothiazole-1, 1-dioxide acting as antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof.
NO20076402L (en) Imaging 18F or 11C-labeled alkylthiophenyl guanidines
NO20076145L (en) Ureadeviates, processes for their preparation and use thereof
DK2113502T3 (en) Hydrazide compounds and their use in pharmaceutical compositions for the treatment of cardiovascular disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004270162

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2536975

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006524731

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004270162

Country of ref document: AU

Date of ref document: 20040820

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004270162

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004781571

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004781571

Country of ref document: EP